MabCampath (alemtuzumab)-Important Safety Information from Bayer HealthCare as approved by the Irish Medicines Board

Notice type: 3rd Party Publications

Date: 11/02/2008

Problem Or Issue:
Please find herewith an important safety communicatin from Bayer on six infection-related deaths reported after treatment with MabCampath(alemtuzumab) following Fludarabine+Rituximab inductions in patients with B-Cell Chronic Lymphocytic Leukemia (CLL).

« Back